Although targeted inhibition of CHEK1 with prexasertib monotherapy showed no considerable tumor regression effect, combining prexasertib with cisplatin significantly reduced the tumor volume compared with cisplatin monotherapy [100]. This evidence concerns the gene CHEK1 and neoplasm.